Pharos iBio Past Earnings Performance
Past criteria checks 0/6
Pharos iBio has been growing earnings at an average annual rate of 3.3%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 100% per year.
Key information
3.3%
Earnings growth rate
20.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -100.0% |
| Return on equity | -45.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Pharos iBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -10,493 | 3,331 | 8,126 |
| 31 Mar 24 | 0 | -9,809 | 3,362 | 7,256 |
| 31 Dec 23 | 0 | -8,858 | 3,226 | 6,138 |
| 30 Sep 23 | 0 | -9,540 | 3,235 | 7,118 |
| 31 Mar 23 | 300 | -15,141 | 3,030 | 7,021 |
| 31 Dec 22 | 300 | -17,062 | 2,988 | 7,085 |
| 31 Dec 21 | 57 | -31,471 | 2,459 | 5,544 |
| 31 Dec 20 | 188 | -13,398 | 1,481 | 4,340 |
| 31 Dec 19 | 421 | -4,951 | 1,258 | 1,587 |
Quality Earnings: A388870 is currently unprofitable.
Growing Profit Margin: A388870 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A388870 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.
Accelerating Growth: Unable to compare A388870's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A388870 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A388870 has a negative Return on Equity (-45.87%), as it is currently unprofitable.